Your feedback is important to us!
We invite all our readers to share with us their views and comments about this article.
Disclaimer: Comments submitted by third parties on this site are the sole responsibility of the individual(s) whose content is submitted. The Daily Star accepts no responsibility for the content of comment(s), including, without limitation, any error, omission or inaccuracy therein. Please note that your email address will NOT appear on the site.
Alert: If you are facing problems with posting comments, please note that you must verify your email with Disqus prior to posting a comment. follow this link to make sure your account meets the requirements. (http://bit.ly/vDisqus)
U.S. biotech firm Celladon hopes that its Mydicar treatment can help patients like Lee Adams who have advanced heart failure and rely on so-called Left Ventricular Assist Devices to keep them alive until a donor heart becomes available.Celladon's treatment works by inserting a gene called SERCA2a – the lack of which makes hearts pump weakly – directly into heart cells via a catheter to repair them. Plans for the study were first announced last year and complement an ongoing 250-patient trial, also funded by Celladon, which is investigating the benefits of gene therapy in 250 people with less advanced heart failure from Europe and the U.S.
FOLLOW THIS ARTICLE